Tina Reed
Tina Reed is a seasoned health care journalist with a focus on health care politics, policy, and business. She currently serves as a health care editor for Axios and is the author of the daily Axios Vitals newsletter. In her reporting, she covers a wide range of topics related to the health care industry, including drug approvals, disease outbreaks, and obesity rates. Reed also frequently reports on conflicts of interest and bias in the industry. Prior to joining Axios, Reed worked as a reporter for CNBC and Stat News. She has a Bachelor's degree in Journalism from Northeastern University.
Biography:
https://www.axios.com/authors/treed
76%
The Daily's Verdict
This author has a mixed reputation for journalistic standards. It is advisable to fact-check, scrutinize for bias, and check for conflicts of interest before relying on the author's reporting.
Bias
88%
Examples:
- Some articles contain language that could be interpreted as implying a connection between certain medications and mental health issues, which may be misleading.
- The articles exhibit a slight bias towards providing information on the negative consequences of not addressing health issues such as obesity and mental health.
Conflicts of Interest
75%
Examples:
- However, it appears that these instances are handled with integrity and transparency.
- There are a few instances where conflicts of interest could potentially arise, such as the coverage of Eli Lilly's Alzheimer's drug.
Contradictions
86%
Examples:
- The article on melatonin use in children reports contradictory information about the relationship between adult usage and pediatric exposure.
- There are instances where the articles report contradictory information regarding the use of specific drugs for different conditions, such as GLP-1 drugs for obesity and diabetes.
Deceptions
60%
Examples:
- However, these instances are relatively minor and do not appear to be a pervasive issue in Tina Reed's reporting.
- There are a few instances where the articles contain deceptive practices, such as misleading statements about the impact of certain medications on mental health.
Recent Articles
GLP-1 Receptor Agonists Shift from Diabetes to Obesity Treatment: Implications and Trends
Broke On: Tuesday, 23 July 2024Since around 2020, GLP-1 receptor agonists (GLP-1 RAs) have seen a notable shift from treating type 2 diabetes to obesity in the US. This trend is driven by FDA approvals and the high prevalence of obesity, accounting for over 88% of new prescriptions being semaglutide. However, this shift raises concerns about potential drug shortages and disparities in access. 
Bird Flu Outbreak Affects 100 Million Poultry Birds in US: Human Cases Reported in Nine Individuals and Over 160 Dairy Herds
Broke On: Tuesday, 16 July 2024Bird flu, affecting over 100 million poultry birds across 48 US states and leading to nine human cases, has spread to dairy herds in a multistate outbreak. Extreme heat challenges farm workers' ability to follow safety precautions, such as wearing protective gear and using cooling systems that can spread the virus. Public health officials urge strong biosecurity practices and provide protective gear from the Strategic National Stockpile, while the CDC investigates the outbreak and advises against vaccination. 
FDA Approves Eli Lilly's Donanemab: A New Hope for Early Alzheimer's Disease Patients
Broke On: Tuesday, 02 July 2024The FDA approves Eli Lilly's donanemab, the second drug for treating early Alzheimer's symptoms. This first-of-its-kind treatment targets amyloid protein deposits in the brain and slows down disease progression, allowing patients to live more independently. Despite reported side effects, benefits outweigh risks with a 39% reduced risk of clinical stage progression. Donanemab costs $12,522 for six months or about $32,000 per year. 
New Study Reveals Which Antidepressants Are Most Likely to Cause Weight Gain
Broke On: Monday, 01 July 2024A recent study published in the Annals of Internal Medicine found that escitalopram and paroxetine users gained roughly 1 pound more than sertraline users after six months, with a higher likelihood of gaining at least 5% of their baseline weight. Bupropion saw the least amount of weight gain among first-line antidepressants. The study offers more detailed information on antidepressant impact on weight gain and aims to help providers and patients make informed decisions. 
CDC and Wastewater Data Show COVID-19 Cases on the Rise: Midwest, Northeast, and South See Increase in Viral Loads
Broke On: Thursday, 27 June 2024CDC data and wastewater surveillance indicate a rise in COVID-19 cases, driven by new variants KP.3 and KP.2, with 39 states experiencing growth or likely growth as of the latest data. Experts attribute this increase to indoor gatherings during summer heat and the July 4 travel period. While this summer wave is expected to remain mild, individuals should remain vigilant, particularly those who are medially vulnerable. Houston wastewater viral load has increased by 273%, prompting local health officials to encourage precautions. 
Bird Flu Spreads in US: Over 100 Dairy Cattle Herds Affected, Milk Production Decreases in Texas and Kansas
Broke On: Tuesday, 18 June 2024Bird flu, a highly contagious virus affecting birds and impacting dairy cattle herds across the US since March 2024, has led to decreased milk production in Texas and Kansas. The H5N1 strain has been detected in over 80 million chickens, wild birds, and mammals globally. Experts warn of potential undetected cases among cows and humans due to limited testing availability. Farmers are advised to implement biosecurity measures, vaccinations, and testing to prevent further spread. 
Avian Flu Spreads Among Dairy Cattle: Concerns Over Human Transmission and Data Gaps
Broke On: Monday, 17 June 2024Growing concerns over the spread of avian flu among dairy cattle in the US, with at least 94 herds testing positive across 12 states. Experts worry about increased human transmission risk and the potential for virus mutation. Michigan is a hotspot despite no known outbreaks, as wastewater shows high levels of H5 influenza A virus. Lack of data on avian flu spread in dairy herds leaves federal government without sufficient information to contain the issue. 
FDA Approves Moderna's RSV Vaccine for Older Adults: A New Weapon Against Respiratory Disease
Broke On: Friday, 31 May 2024Moderna's RSV vaccine, mResvia, has received FDA approval for older adults, marking the second product from the company to be approved after its Covid-19 vaccine. The vaccine is designed to protect against lower respiratory tract disease caused by RSV infection in adults aged 60 and above. With an 83.7% efficacy rate, mResvia will join GlaxoSmithKline's Arexvy and Pfizer's Abrysvo as crucial tools for protecting older adults during the upcoming RSV season. 
New USPSTF Guidelines: Mammograms Every Other Year for Women Aged 40 and Above
Broke On: Tuesday, 30 April 2024The US Preventive Services Task Force now recommends that women get mammograms every other year starting at age 40, following rising breast cancer rates among younger women. The new guidelines bring the USPSTF closer in line with other health organizations and require insurers to cover mammograms for women in their 40s, but concerns remain over potential harms and costs for supplemental screening. 
Walgreens Expands Specialty Pharmacy Business with Focus on Gene and Cell Therapies: New Facility, 1,500 Specialty-Trained Pharmacists, and $24 Billion Market
Broke On: Thursday, 25 April 2024Walgreens launches Walgreens Specialty Pharmacy, a $24 billion business focusing on gene and cell therapies, integrating new services with existing assets. The expansion includes an 18,000-sqft facility in Pittsburgh to manage complex supply chains for high-cost treatments like cancer and HIV. With over 1,500 specialty-trained pharmacists and 5,000 patient advocacy team members, Walgreens Specialty Pharmacy aims to improve financial performance through expanded offerings in the specialty pharmacy market.